CARTITUDE-1: Long-Term Efficacy Update From EHA 2025 (Part 1)
Panelists discuss how some patients in CARTITUDE-1 maintained stringent complete remission for more than 5 years without further treatment, potentially redefining the concept of cure in myeloma.
EP: 1.Treatment Approaches in Multiple Myeloma
EP: 2.FDA Approvals for Multiple Myeloma
EP: 3.CARTITUDE-1 Baseline Demographics
EP: 4.An Overview of CARTITUDE-1
EP: 5.CARTITUDE-1 Patients
EP: 6.CARTITUDE-1 Efficacy Findings
EP: 7.CARTITUDE-1 Safety Overview
EP: 8.CARTITUDE-1 Primary Findings Discussion
EP: 9.CARTITUDE-1: Long-Term Efficacy Update From EHA 2025 (Part 1)
EP: 10.CARTITUDE-1: Long-Term Efficacy Update From EHA 2025 (Part 2)
Further analysis highlighted that 12 patients maintained minimal residual disease–negative complete remission for more than 5 years without maintenance therapy. These “one-and-done” responses represent a new standard for defining potential cure in myeloma.
This finding redefines expectations in multiple myeloma, where continuous therapy has long been the norm. The absence of relapse in these patients supports the possibility of true functional cures using chimeric antigen receptor T-cell therapy.
Ongoing randomized trials, such as CARTITUDE-5 and CARTITUDE-6, aim to evaluate ciltacabtagene autoleucel in frontline settings and as a potential alternative to autologous stem cell transplant, further advancing the goal of curative therapy.
